CL2023001924A1 - Agonistas del glp-1 heterocíclicos (solicitud divisional 374-2023) - Google Patents
Agonistas del glp-1 heterocíclicos (solicitud divisional 374-2023)Info
- Publication number
- CL2023001924A1 CL2023001924A1 CL2023001924A CL2023001924A CL2023001924A1 CL 2023001924 A1 CL2023001924 A1 CL 2023001924A1 CL 2023001924 A CL2023001924 A CL 2023001924A CL 2023001924 A CL2023001924 A CL 2023001924A CL 2023001924 A1 CL2023001924 A1 CL 2023001924A1
- Authority
- CL
- Chile
- Prior art keywords
- glp
- agonists
- heterocyclic
- divisional application
- solvates
- Prior art date
Links
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title abstract 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title abstract 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta divulgación se refiere a agonistas del GLP-1 de Fórmula I que incluye sales y solvatos farmacéuticamente aceptables de estos y composiciones farmacéuticas que los incluyen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020107437 | 2020-08-06 | ||
| CN2021073958 | 2021-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001924A1 true CL2023001924A1 (es) | 2024-02-16 |
Family
ID=80117080
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000374A CL2023000374A1 (es) | 2020-08-06 | 2023-02-03 | Agonistas del glp-1 heterocíclicos |
| CL2023001924A CL2023001924A1 (es) | 2020-08-06 | 2023-06-28 | Agonistas del glp-1 heterocíclicos (solicitud divisional 374-2023) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000374A CL2023000374A1 (es) | 2020-08-06 | 2023-02-03 | Agonistas del glp-1 heterocíclicos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11897851B2 (es) |
| EP (1) | EP4192831A4 (es) |
| JP (1) | JP2023537501A (es) |
| KR (1) | KR20230053620A (es) |
| CN (1) | CN116323599A (es) |
| AU (1) | AU2021323253A1 (es) |
| CA (1) | CA3190163A1 (es) |
| CL (2) | CL2023000374A1 (es) |
| CO (1) | CO2023001263A2 (es) |
| CR (1) | CR20230066A (es) |
| DO (1) | DOP2023000023A (es) |
| IL (1) | IL300155A (es) |
| MX (1) | MX2023001311A (es) |
| PE (1) | PE20231181A1 (es) |
| TW (1) | TW202220973A (es) |
| WO (1) | WO2022028572A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116323599A (zh) | 2020-08-06 | 2023-06-23 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| EP4204415A1 (en) | 2020-08-28 | 2023-07-05 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2022202864A1 (ja) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| WO2022219495A1 (en) * | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2023038039A1 (ja) | 2021-09-08 | 2023-03-16 | 塩野義製薬株式会社 | 抗肥満作用の関与する疾患の予防及び治療用医薬 |
| KR20240073108A (ko) | 2021-10-05 | 2024-05-24 | 아스트라제네카 아베 | Glp-1 수용체 조절제로서의 특정 2,5-디아자바이시클로[4.2.0]옥탄 |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| WO2023106310A1 (ja) * | 2021-12-07 | 2023-06-15 | 塩野義製薬株式会社 | Ｇｌｐ－１受容体アゴニスト活性を有する芳香族複素環誘導体 |
| WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023151574A1 (en) * | 2022-02-09 | 2023-08-17 | Gasherbrum Bio Inc. | Heterocyclic glp-1 agonists |
| WO2023151575A1 (en) * | 2022-02-09 | 2023-08-17 | Gasherbrum Bio Inc. | Heterocyclic glp-1 agonists |
| TW202342014A (zh) * | 2022-02-10 | 2023-11-01 | 瑞士商諾華公司 | １，３－苯并二氧戊環衍生物 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| WO2024107781A1 (en) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6628343B1 (en) | 1997-05-23 | 2003-09-30 | Sony Corporation | Television signal reception circuit, automatic phase shift control circuit and equal amplitude addition circuit |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| ATE461217T1 (de) | 2003-12-18 | 2010-04-15 | Novo Nordisk As | Glp-1-verbindungen |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| WO2008012623A1 (en) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
| US8420655B2 (en) | 2009-12-04 | 2013-04-16 | Boehringer Ingelheim International Gmbh | Benzimidazole inhibitors of leukotriene production |
| US9758560B2 (en) | 2011-09-06 | 2017-09-12 | Novo Nordisk A/S | GLP-1 derivatives |
| BR112015031040A8 (pt) | 2013-06-11 | 2018-01-02 | Receptos Inc | Novos moduladores do receptor de glp-1 |
| ES2819534T3 (es) | 2014-07-25 | 2021-04-16 | Receptos Llc | Derivados de pirimidina como moduladores del receptor GLP-1 |
| BR112018013525A2 (pt) | 2015-12-31 | 2018-12-04 | Hanmi Pharm. Co., Ltd. | conjugado de longa atuação de agonista de receptor de glucagon/glp-1/gip triplo e composição farmacêutica |
| JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| WO2018059314A1 (zh) | 2016-09-28 | 2018-04-05 | 四川科伦博泰生物医药股份有限公司 | 氮杂双环衍生物及其制备方法和用途 |
| CN108017636A (zh) | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| PL3555064T3 (pl) | 2016-12-16 | 2023-03-06 | Pfizer Inc. | Agoności receptora GLP-1 i ich zastosowania |
| TWI707683B (zh) | 2018-06-13 | 2020-10-21 | 美商輝瑞股份有限公司 | Ｇｌｐ－１受體促效劑及其用途 |
| WO2019239371A1 (en) | 2018-06-15 | 2019-12-19 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CR20210110A (es) | 2018-08-31 | 2021-05-13 | Pfizer | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas |
| KR20210106447A (ko) | 2018-11-22 | 2021-08-30 | 치루 레고르 테라퓨틱스 인코포레이티드 | Glp-1r 효능제 및 그의 용도 |
| WO2020117987A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of liver disorders |
| KR20210152513A (ko) | 2019-04-12 | 2021-12-15 | 치루 레고르 테라퓨틱스 인코포레이티드 | Glp-1r 작용제 및 이의 용도 |
| CA3140972C (en) | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2021018023A1 (zh) | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| BR112022007627A2 (pt) | 2019-10-25 | 2022-07-12 | Gilead Sciences Inc | Compostos moduladores do glp-1r |
| BR112022009287A2 (pt) | 2019-11-15 | 2022-08-09 | Ildong Pharmaceutical Co Ltd | Agonista do receptor de glp-1 e uso do mesmo |
| CN114761395A (zh) | 2019-12-02 | 2022-07-15 | 现代药品株式会社 | Glp-1受体激动剂 |
| EP4097097A1 (en) | 2020-01-29 | 2022-12-07 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US20230165846A1 (en) | 2020-02-13 | 2023-06-01 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| TWI825398B (zh) | 2020-03-18 | 2023-12-11 | 南韓商Ｌｇ化學股份有限公司 | Glp-1 受體促效劑、包含該促效劑之醫藥組成物及其製備方法 |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| CN113493447B (zh) | 2020-04-03 | 2024-06-11 | 轩竹(北京)医药科技有限公司 | Glp-1受体激动剂 |
| US20230295154A1 (en) | 2020-04-29 | 2023-09-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP7359974B2 (ja) | 2020-06-04 | 2023-10-11 | ハンチョウ サイウィンド バイオサイエンスィズ カンパニー リミテッド | 五員環ヘテロ芳香族イミダゾール系化合物及びその使用 |
| CN113773310B (zh) | 2020-06-10 | 2023-12-22 | 重庆康丁医药技术有限公司 | 一种具有心血管益处的glp-1小分子 |
| WO2021249492A1 (zh) | 2020-06-10 | 2021-12-16 | 南京明德新药研发有限公司 | 甲基取代的苯并二噁唑类化合物及其应用 |
| CN113801136B (zh) | 2020-06-16 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用 |
| CN113816948B (zh) | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| CN115916772A (zh) | 2020-06-19 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
| WO2021259309A1 (zh) | 2020-06-24 | 2021-12-30 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
| CN116323599A (zh) | 2020-08-06 | 2023-06-23 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| AR123156A1 (es) | 2020-08-06 | 2022-11-02 | Qilu Regor Therapeutics Inc | Agonistas de glp-1r y sus usos |
| WO2022040600A1 (en) | 2020-08-21 | 2022-02-24 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| EP4204415A1 (en) | 2020-08-28 | 2023-07-05 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN115884969A (zh) | 2020-09-01 | 2023-03-31 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| WO2022068772A1 (zh) | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| WO2022078152A1 (zh) | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
| JP2023546054A (ja) | 2020-10-13 | 2023-11-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| US20230391760A1 (en) | 2020-10-13 | 2023-12-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| CA3200245A1 (en) | 2020-11-27 | 2022-06-02 | Junjun Wu | Benzimidazole derivative and preparation method therefor and medical use thereof |
| CN114591296A (zh) | 2020-12-02 | 2022-06-07 | 海思科医药集团股份有限公司 | 一种glp-1r激动剂及其在医药上的应用 |
| CN114591308B (zh) | 2020-12-03 | 2024-03-08 | 苏州闻泰医药科技有限公司 | 一类glp-1r受体激动剂化合物及其用途 |
| CN114634510A (zh) | 2020-12-16 | 2022-06-17 | 杭州中美华东制药有限公司 | 咪唑并吡啶衍生物及其用途 |
| WO2022135572A1 (zh) | 2020-12-25 | 2022-06-30 | 四川海思科制药有限公司 | 一种五并五元环衍生物及其在医药上的应用 |
| CN114763352A (zh) | 2021-01-15 | 2022-07-19 | 海思科医药集团股份有限公司 | 一种glp-1受体激动剂及其在医药上的应用 |
| US20230089073A1 (en) | 2021-01-28 | 2023-03-23 | Carmot Therapeutics, Inc. | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| CN114907351A (zh) | 2021-02-07 | 2022-08-16 | 杭州中美华东制药有限公司 | 三环类glp-1受体激动剂及其用途 |
| US20220306614A1 (en) | 2021-03-11 | 2022-09-29 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US20240208952A1 (en) | 2021-03-22 | 2024-06-27 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Thiophene glp-1 receptor agonist and use thereof |
| EP4313963A1 (en) | 2021-03-24 | 2024-02-07 | Eccogene Inc. | Phenyl- [1, 3] dioxolo [4, 5-c] pyridinyl-phenyl-, phenyl- [1, 3] dioxolo [4, 5-c] pyridinyl-heteroaryl-, or phenyl- [1, 3] dioxolo [4, 5-c] pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo [d] imidazole-carboxylic acid derivatives and methods of using same |
| WO2022202864A1 (ja) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| US20240300928A1 (en) | 2021-04-08 | 2024-09-12 | Lg Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| WO2022219495A1 (en) * | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| CN117177970A (zh) * | 2021-04-30 | 2023-12-05 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
| CN113480534B (zh) | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| CN114716423A (zh) | 2022-05-20 | 2022-07-08 | 中国科学院上海药物研究所 | 5,6-二氢-1,2,4-三嗪类化合物及其作为glp-1受体激动剂的药学用途 |
-
2021
- 2021-08-06 CN CN202180067810.7A patent/CN116323599A/zh active Pending
- 2021-08-06 PE PE2023000215A patent/PE20231181A1/es unknown
- 2021-08-06 MX MX2023001311A patent/MX2023001311A/es unknown
- 2021-08-06 JP JP2023507783A patent/JP2023537501A/ja active Pending
- 2021-08-06 EP EP21853586.2A patent/EP4192831A4/en active Pending
- 2021-08-06 WO PCT/CN2021/111193 patent/WO2022028572A1/en active Application Filing
- 2021-08-06 TW TW110129129A patent/TW202220973A/zh unknown
- 2021-08-06 CR CR20230066A patent/CR20230066A/es unknown
- 2021-08-06 AU AU2021323253A patent/AU2021323253A1/en active Pending
- 2021-08-06 KR KR1020237007693A patent/KR20230053620A/ko active Search and Examination
- 2021-08-06 CA CA3190163A patent/CA3190163A1/en active Pending
- 2021-08-06 IL IL300155A patent/IL300155A/en unknown
-
2023
- 2023-02-03 DO DO2023000023A patent/DOP2023000023A/es unknown
- 2023-02-03 CO CONC2023/0001263A patent/CO2023001263A2/es unknown
- 2023-02-03 CL CL2023000374A patent/CL2023000374A1/es unknown
- 2023-02-06 US US18/106,378 patent/US11897851B2/en active Active
- 2023-06-28 CL CL2023001924A patent/CL2023001924A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023001311A (es) | 2023-04-18 |
| WO2022028572A1 (en) | 2022-02-10 |
| CA3190163A1 (en) | 2022-02-10 |
| EP4192831A1 (en) | 2023-06-14 |
| JP2023537501A (ja) | 2023-09-01 |
| US20230192633A1 (en) | 2023-06-22 |
| TW202220973A (zh) | 2022-06-01 |
| AU2021323253A8 (en) | 2023-03-16 |
| US11897851B2 (en) | 2024-02-13 |
| EP4192831A4 (en) | 2024-05-15 |
| IL300155A (en) | 2023-03-01 |
| DOP2023000023A (es) | 2023-02-28 |
| CR20230066A (es) | 2023-05-29 |
| CN116323599A (zh) | 2023-06-23 |
| CL2023000374A1 (es) | 2023-11-03 |
| KR20230053620A (ko) | 2023-04-21 |
| CO2023001263A2 (es) | 2023-05-19 |
| AU2021323253A1 (en) | 2023-02-23 |
| PE20231181A1 (es) | 2023-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001924A1 (es) | Agonistas del glp-1 heterocíclicos (solicitud divisional 374-2023) | |
| DOP2022000158A (es) | Agonistas heterocíclicos de glp-1 | |
| UY39296A (es) | Azaquinolonas sustituidas inhibidoras de parp y composiciones farmacéuticas que las contienen | |
| GT200500379A (es) | Derivados fusionados de pirazol y metodos de tratamiento de trastornos metabolicos con estos | |
| ECSP22071009A (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
| CO2018008759A2 (es) | Inhibidores de mcl-1 y métodos de uso de los mismos | |
| CL2023001219A1 (es) | Compuestos de pirimidina, composiciones y aplicaciones médicas de esta. | |
| ECSP22049160A (es) | Derivados de bencimidazol | |
| UY38559A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| AR127470A1 (es) | Inhibidores de lrrk2 | |
| CL2022002386A1 (es) | Compuestos de amino pirimidina fusionados | |
| CO2023017151A2 (es) | Inhibidores de ripk1 de nicotinamida | |
| BR112021020234A2 (pt) | Terapia de combinação que compreende compostos da fórmula (i) e agonistas de receptor de glp-1 | |
| ECSP055673A (es) | Derivados de 4-(3,5-dicianofenoxi) pirazol para el uso como moduladores de transcriptasa reversa en el tratamiento del vih | |
| AR124720A1 (es) | Derivados de pirazolamida | |
| CL2022002405A1 (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana | |
| AR128426A1 (es) | Compuestos heterocíclicos y métodos de uso | |
| CO2024011857A2 (es) | Compuestos de uracilo n3-sustituidos como inhibidores de trpa1 | |
| CO2024010726A2 (es) | Compuestos heterocíclicos y métodos de uso | |
| AR129367A1 (es) | Derivados de pirazol como agonistas de sting | |
| AR129588A1 (es) | Inhibidores de kras | |
| ECSP23075535A (es) | Compuestos cíclicos y métodos de uso | |
| AR118065A1 (es) | Compuesto hidroxipiridoxazepina y composición farmacéutica que lo comprende | |
| ECSP22091230A (es) | Derivados de n-(piperidin-4-il)benzamida de acción luminal | |
| CL2023000970A1 (es) | Espiro derivados de alfa-d-galactopiranosidos |